A recent report from the STOP-NIDDM trial showed that the rare polymorphism of PPARD gene in linkage disequilibrium with the rs2267668 polymorphism was studied here and the 482Ser allele of the PPARGC1A rs8192678 polymorphism had the additive effects on the risk of type 2 diabetes [22], which makes the combined effects of these polymorphisms on the risk of CKD also an issue of interest. Here, PPARD is linked to type 2 diabetes mellitus.